Table 1.
Baseline Demographic and Clinical Characteristics of the Patients.
| Characteristic | Total (N = 85) |
|---|---|
| Age | |
| Median — yr | 66 |
| Range — yr | 37–82 |
| ≥70 yr — no. (%) | 30 (35) |
| Sex — no. (%) | |
| Male | 65 (76) |
| Female | 20 (24) |
| Diagnosis — no. (%) | |
| Chronic lymphocytic leukemia | 82 (96) |
| Small lymphocytic lymphoma | 3 (4) |
| Time since most recent systemic anticancer therapy — mo | |
| Median | 3 |
| Range | 1–98 |
| Rai stage at treatment initiation — no. (%)* | |
| 0, I, or II | 29 (34) |
| III or IV | 55 (65) |
| Data missing | 1 (1) |
| No. of previous therapies | |
| Median | 4 |
| Range | 1–12 |
| Previous therapy — no. (%) | |
| Nucleoside analogue | 81 (95) |
| Rituximab | 83 (98) |
| Alkylator | 76 (89) |
| Alemtuzumab | 18 (21) |
| Bendamustine | 33 (39) |
| Ofatumumab | 22 (26) |
| Bulky nodes — no. (%) | |
| ≥5 cm in diameter | 44 (52) |
| ≥10 cm in diameter | 13 (15) |
| Data missing | 3 (4) |
| Unmutated immunoglobulin variable-region heavy-chain gene — no. (%) | |
| Patients with data that could be evaluated | 69 (81) |
| Data missing | 4 (5) |
| Interphase cytogenetic abnormality — no. (%)† | |
| 17p13.1 deletion | 28 (33) |
| 11q22.3 deletion | 31 (36) |
| β2-microglobulin level — no. (%) | |
| >3 mg/liter | 39 (46) |
| Data missing | 5 (6) |
| Disease resistant to purine analogue — no. (%)‡ | 41 (48) |
*
Rai stage 0 indicates low-risk, stage I or II intermediate-risk, and stage III or IV high-risk disease.
†
Cutoff points were defined according to the assay specifications as performed in the central laboratory.
‡
Resistance to a purine analogue was defined as treatment failure (stable disease or progressive disease) or disease progression within 12 months after receipt of a regimen containing a purine analogue.